Introduction
A generally accepted immunosuppressive regimen two years after renal transplantation is prednisolone, 10-15 mg daily, and azathioprine. We have shown that azathioprine may be safely stopped in some renal transplant recipients. ' Long-term treatment with prednisolone is associated with several undesirable side effects. We therefore reduced the dosage of prednisolone in patients who were not taking any other form of immunosuppressive treatment two years after transplantation to the lowest value compatible with graft survival. A preliminary account of this work has been reported. 2 We now describe the follow-up of these patients with special reference to their plasma drug concentrations and adrenal function.
Patients and methods
Ten patients with renal transplants who had not taken azathioprine for 3-31 months were included in the study (see table I ). Full clinical details have been published elsewhere.2 Side effects associated with steroid treatment included hypertension, obesity, Cushingoid facial features, hypertriglyceridaemia, avascular necrosis of bone, and acne. The plasma creatinine concentrations at the beginning of the study were normal (70-140 ,umol/l; 0-8-1-6 mg/100 ml) in all patients except one (case 3: concentration 170 imol/l; 1 9 mg/100 ml).
All patients were taking 10 mg of prednisolone daily (two 5 mg enteric-coated tablets) at the start of the study. This was reduced by 1 mg at monthly intervals by replacing one of the 5 mg tablets with the appropriate number of 1 mg tablets. Blood was taken at 9 am after an overnight fast and subsequently one, three, and six hours after an oral dose of prednisolone. Plasma was separated immediately and stored at -20°C until assayed. Prednisolone concentration was measured by radioimmunoassay3 and cortisol by a standard fluorometric method, the within-batch and between-batch coefficients of variation for the prednisolone radioimmunoassay being 5 0% and 6 5 % respectively. All assays were performed in duplicate, and samples were reassayed if duplicate values differed by more than 10%. The time intervals of one, three, and six hours for measuring prednisolone concentrations were chosen in accordance with the absorption characteristics of the two different prednisolone preparations used: standard nonenteric-coated tablets produce peak plasma concentrations one hour after administration, whereas enteric-coated tablets produced peak concentrations after about three hours. The plasma concentration of the drug remains high for about six hours.4
In five patients (cases 1, 2, 3, 8, and 10) the adrenal response to corticotrophin was monitored by measuring plasma cortisol concentrations before and one, three, and six hours after an intramuscular injection of 2 mg tetracosactrin (Synacthen Depot).6
Results
The lowest dose of prednisolone reached in the 10 patients was 1-6 mg daily ( 110 [smol/l (1-2 mg/100 ml) at the end of the study.
Mean creatinine clearance was then 43 6 ml/min. In case 9 acute deterioration in renal function due to acute pyelonephritis was treated successfully. The dose of prednisolone was not reduced below 5 mg in case 10 because of lethargy and severe weight loss. In the remaining three patients (cases 1-3) the daily dose of prednisolone was reduced to 1, 1, and 5 mg respectively. Mean serum creatinine concentration remained stable. In cases 2 and 3 there was total compatibility of HLA matching.
After oral prednisolone doses of 7-10 mg the plasma prednisolone concentrations were not proportional to the size of the dose (table II) . No clear and consistent pattern of differences in plasma drug concentrations was seen either between groups or between patients to explain the different clinical courses or the plasma cortisol values found at various doses of prednisolone. Most patients had low plasma cortisol concentrations at the beginning of the study, and those patients who showed signs of rejection tended to have cortisol concentrations at the lower limit of the normal range.
Of the five patients who were taking 5 mg or less of prednisolone daily, four produced a subnormal response to intramuscular tetracosactrin (fig 3) . These included one patient (case 8) who subsequently developed severe rejection while taking 2 mg of prednisolone daily and another (case 10) in whom the gradual withdrawal of prednisolone was stopped when he developed symptoms of hypoadrenalism.
Discussion
Our study shows that in some renal transplant recipients there is sufficient graft-host tolerance to permit almost complete discontinuation of immunosuppressive treatment. Di Padova et al7 reported a case in which no untoward effects were seen more than two years after a patient had stopped taking immunosuppressive treatment. This, however, must be viewed with caution because we find that even a gradual reduction ofthe prednisolone dose is likely to precipitate episodes of rejection. Unlike the observations of Owens et al,8 we found that such episodes of rejection could be catastrophic. One patient (case 6; table I) developed acute rejection then a rapidly progressing chronic rejection, eventually requiring dialysis-a history similar to that described by Lokkegaard et al.9 In cases 7 and 8 (figs 1 and 2) the initial episode of rejection was easily reversed by increasing the dose of oral prednisolone, but this was followed by a rapid deterioration in renal function that occurred while the patients were taking higher doses of oral prednisolone. In case 8 this deterioration was controlled, but only by intravenous pulses of methylprednisolone. In case 7, however, there was severe and irreversible damage to renal function.
Attempts have been made to define the minimal dose of steroid below which rejection is likely to occur.'0 Those patients in whom episodes of rejection occurred more than 24 months after renal transplantation were receiving a mean dose of prednisolone at the time of rejection of 130± SD 30 [tg/kg body weight. In another series," rejection occurred in three patients when they were taking 100, 130, or 160 ,ug/kg. Our findings, however, suggest that the requirements for immunosuppressive drugs vary between patients, so that a standard "minimumthreshold dose" is unlikely to be generally applicable. Thus five of our patients who developed rejection were taking between 30 and 75 tg prednisolone/kg daily, whereas three patients taking similar doses (cases 1-3) remained well and maintained stable renal function.
Subjects vary in their handling of oral prednisolone."" We studied the relation between the dose of prednisolone and the plasma concentration after the oral administration of four small, different doses of either enteric-coated prednisolone or entericcoated and standard prednisolone. There were no consistent differences in plasma prednisolone concentration among patients at the doses of prednisolone used. This was so even after the 10 mg dose (two 5 mg enteric-coated tablets) was given. The large individual variations in plasma prednisolone concentration after the same dose of prednisolone did not seem to be implicated in the episodes of rejection seen in some patients.
The plasma cortisol concentrations in these patients tended to be below normal or at the lower end of the normal range, which was also apparently inconsistent with the patterns of plasma prednisolone concentrations. Four of the five patients in whom adrenal function was assessed showed moderate to severe impairment (fig 3) . The response to tetracosactrin in one of these patients (case 8), who subsequently developed rejection, however, was not distinguishable from that seen in the other three patients (cases 2, 3 and 10; fig 3) . Our 
